Rademikibart Drug Asset Due Diligence Report 2026

This Rademikibart Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Rademikibart can convert its Monoclonal antibody profile and IL-4Rα biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Rademikibart (query alias: Rademikibart)
Modality / target	Monoclonal antibody; IL-4Rα; IL-4Rα inhibitors
Highest global status	NDA/BLA
Originator	Suzhou Connect Biopharma Co. Ltd.
Active developers	Suzhou Connect Biopharma Co. Ltd., Simcere Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group Ltd.

The MCP disease footprint includes Dermatitis, Atopic, Moderate Atopic Dermatitis, Severe Atopic Dermatitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06940154	Phase 2	Active, not recruiting	160	Treatment failure rate
NCT06940141	Phase 2	Active, not recruiting	160	Treatment failure rate within 28 days after randomization
NCT07705737	Phase 2	Not yet recruiting	40	Change from baseline in post-BD FEV1

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Rapid Improvement in Lung Function Observed With Rademikibart in Patients With Moderate-to-Severe Uncontrolled Asthma

Phase 2; n=322; evaluation: Positive. Reported fields: FEV1 = 175 mL ; FEV1 = 232 mL

Efficacy of Rademikibart in COPD-like Patients: Sub-analyses From the Phase 2b Trial in Patients With Moderate-to-Severe Asthma

Phase 2; n=322; evaluation: Positive. Reported fields: Pre-BD FEV1 at Week 12 = 160 mL ( 0 - 320); Pre-BD FEV1 at Week 12 = 160 mL ( -40 to 370)

Rademikibart Treatment for Moderate-to-Severe Uncontrolled Asthma: A Phase 2B Randomized Clinical Trial

Phase 2; n=322; evaluation: Positive. Reported fields: FEV1 = 189 mL ( 92 - 286); FEV1 = 140 mL ( 44 - 236)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Rademikibart addresses Dermatitis, Atopic, Moderate Atopic Dermatitis, Severe Atopic Dermatitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-11-21	Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China	Phase 3	US$21.0M upfront; US$120.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO